MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease

R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh (Overland Park, KS, USA)

Meeting: 2018 International Congress

Abstract Number: 369

Keywords: Wearing-off fluctuations

Session Information

Date: Saturday, October 6, 2018

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: Post-hoc analysis of subjects with Parkinson’s disease (PD) achieving > 30% reduction in UPDRS motor score (UPDRSIII) from pre- to post-dose over the first hour of treatment with placebo or CVT-301, a levodopa inhalation powder in development for the treatment of OFF periods.

Background: In a 12-week, randomized, double-blind, placebo-controlled study of 339 subjects experiencing OFF periods, CVT-301 84mg significantly improved motor function, measured by an improvement in UPDRSIII score pre-dose to 30 minutes post-dose at 12 weeks. In addition 57.7% of subjects in the CVT-301 84mg group turned ON within 60 minutes and maintained ON through the 60 minute assessment compared with 36.1% in the placebo group (p=0.003). Reduction of >30% in UPDRSIII has been used previously as a marker of improvement in response to levodopa and other treatments.

Methods: UPDRSIII score was measured at 10, 20, 30 and 60 minutes post-dose with CVT-301 60mg and 84mg vs placebo. Post-hoc analysis evaluated the percent of subjects with > 30% reduction in total UPDRSIII score pre- to post-dose within the first hour. The percentage of subjects in the CVT-301 60mg and 84mg groups who achieved > 30% reduction in total UPDRSIII score at each of the assessment time points, and the average across all time points, were compared to placebo. Other analyses were also conducted.

Results: Significant findings at 12 weeks included a greater percentage of CVT-301 treated subjects achieving a > 30% reduction in UPDRSIII compared to placebo at 30 minutes (52% for CVT-301 84mg, p=0.015; 53% for CVT-301 60 mg, p=0.011; 35% for placebo). 27% of CVT-301 84mg subjects achieved > 30% reduction in UPDRSIII at 10 min, which was significantly greater compared to 14% in the placebo group (p=0.019); the 60mg group did not achieve significance (24%, p=0.08). Averaged across all time points, the percentage of CVT-301 treated subjects with > 30% reduction in UPDRSIII was greater than placebo (45% for CVT-301 84mg, p=0.02; 45% for CVT-301 60mg, p=0.02; 29% for placebo).

Conclusions: In this Phase 3 study a greater proportion of CVT-301 treated subjects had clinically relevant improvements in their motor function by achieving >30% reduction in UPDRSIII compared to placebo. These observations further support the efficacy of CVT-301 in treatment of OFF periods.

To cite this abstract in AMA style:

R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh. Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/efficacy-of-cvt-301-levodopa-inhalation-powder-for-treatment-of-off-periods-in-parkinsons-disease/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-of-cvt-301-levodopa-inhalation-powder-for-treatment-of-off-periods-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley